ProfileGDS5678 / 1431451_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 29% 29% 29% 28% 30% 29% 28% 28% 29% 28% 29% 28% 28% 38% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6963529
GSM967853U87-EV human glioblastoma xenograft - Control 22.6558729
GSM967854U87-EV human glioblastoma xenograft - Control 32.6548629
GSM967855U87-EV human glioblastoma xenograft - Control 42.5889228
GSM967856U87-EV human glioblastoma xenograft - Control 52.6354430
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.727529
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6741728
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6242828
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6385629
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6356828
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6398729
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.604228
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6426228
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8610938